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Identity 
Other names: EBP1, HG4-1, ITAF45, p38-2G4 
HGNC (Hugo): PA2G4 
Location: 12q13.2 
Note 
PA2G4 encodes a cell-cycle regulated protein capable 
of interacting with DNA, RNA and protein. The gene 
was isolated as a DNA binding protein (p38-2g4) 
(Radomski and Jost, 1995) and also as an ErbB3-
interacting protein (EBP1) (Yoo et al., 2000). Two 
different isoforms of EBP1 play a role in cell survival, 
cell cycle arrest and differentiation. The long form may 
have an oncogenic function when overexpressed, and 
the short form acts as a tumor suppressor (Liu et al., 
2006). EPB1 also functions as a transcriptional 
repressor of E2F1-regulated genes (Zhang et al., 2004) 
and the androgen receptor (AR) (Zhang et al., 2005) 








The PA2G4 gene contains 13 exons. The sizes of the 
exons 1-13 are 88, 128, 105, 69, 92, 63, 78, 78, 133, 94, 
127, 53 and 65 bp (to the stop codon). Exon 1 contains 
the translation initiation ATG. Exon 13 contains the 
stop codon. 
Transcription 
The human PA2G4 promoter contains several putative 
transcription factor binding sites. The major transcript 
length is 2643 nt. Two proteins are translated due to 
alternative splicing (Liu et al., 2006). An alternatively 
spliced version missing 29 NT between the first and 
third ATGs has been observed. 
The PA2G4 promoter contains two tandem DNA 
elements that bind E2F1. E2F1 increases endogenous 
EBP1 mRNA levels in cancer cells, but decreases 
EBP1 mRNA abundance in non transformed cells 
(Judah et al., 2010). 
Pseudogene 
Six pseudogenes, located on chromosomes 3, 6, 9, 18, 
20 and X, have been identified. 
 
The alignment of PA2G4 mRNA to its genomic sequence. 
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The linear schematic of EBP1. Functional domains, including Nucleolar Localization Signal (NuLS), σ70 RNA binding region (σ70), 




p38-2G4 was initially isolated as a DNA binding 
protein from mouse Ehrlich ascites cells (Radomski 
and Jost, 1995). The MW of this protein is predicted to 
be 38058 D, consisting of 340 amino acids. The human 
orthologue EBP1 was later identified as an ErbB3 
binding protein of the same MW as the mouse protein 
(Yoo et al., 2000). This form migrates at approximately 
42 kD in SDS-PAGE gels. Later, a larger 394 amino 
acid form (predicted MW 43787 D, migrating at 48 kD) 
was observed in mammalian cells (Xia et al., 2001). 
The two forms have been demonstrated to be the result 
of alternative splicing (Liu et al., 2006) or usage of 
alternative translation initiation sites (Xia et al., 2001). 
Amino acids 1-48 are required for nucleolar 
localization and the C terminal domain (aa 364-394) is 
required for interactions with nucleic acids (Moonie et 
al., 2007) and protein (Zhang et al., 2002). 
EBP1 is post translationally modified at several 
phosphorylation sites (Ser 360 (Ahn et al., 2006), Ser 
363 (Akinmade et al., 2007) and Thr 261 (Akinmade et 
al., 2008)) in vivo. The protein stability of the short 
form is regulated by ubiquitination (Liu et al., 2009). 
The short form is also sumoylated by the TLF/FUS E3 
ligase and this sumoylation is required for the anti-
proliferative effects of EBP1 (Oh et al., 2010). 
The crystal structure of both murine (Monie et al., 
2007) and human (Kowalinski et al., 2007) EBP1 has 
been solved. There is a core domain that is homologous 
to methionine aminopeptidases, although no enzymatic 
activity has been reported. The C terminal domain 
containing a Lys-rich nuclear hormone receptor binding 
motif (LKALL) was reported to mediate RNA binding 
(Monie et al., 2007). 
Expression 
EBP1 has been found to be ubiquitously expressed with 
high expression levels in skeletal muscle (Yoo et al., 
2000). 
Localisation 
Under logarithmically growing conditions in cell 
culture, EBP1 localizes to the nucleolus and the 
cytoplasm (Xia et al., 2001; Squatrito et al., 2004). 
Upon stimulation with the ErbB3 ligand heregulin, the 
short form of EBP1 is recruited to the nucleus in 
AU565 breast cancer cells (Yoo et al., 2000). 
Sumoylation is required for nuclear translocation (Oh 
et al., 2010). In primary normal epithelial cells, EBP1 
is confined to the cytoplasm (Zhang et al., 2008b). 
Function 
EBP1 was initially isolated as a cell cycle-regulated 
DNA binding protein (Radomski and Jost, 1995) and 
has been shown to induce cell cycle arrest in the G2/M 
phase of the cell cycle (Zhang et al., 2005). EBP1 acts 
as a corepressor for several proliferation-associated 
genes including Cyclin D1, E2F1 (Zhang and 
Hamburger, 2004) and the androgen receptor (Zhang et 
al., 2005). EBP1 inhibits transcription of these genes by 
recruiting HDAC2 via Sin3A to the E2F1 and AR-
regulated promoters (Zhang et al., 2005). EBP1 
interacts with RB1 and the interaction is enhanced upon 
EBP1 dephosphorylation (Xia et al., 2001). 
EBP1 was isolated as an ErbB3 binding protein using a 
yeast-two hybrid screen (Yoo et al., 2000). The 
interactions of EBP1 with ErbB3 is disrupted by the 
ErbB3 ligand heregulin, leading to EBP1 nuclear 
translocation. This leads to the eventual inhibition of 
heregulin-stimulated proliferation, presumably due to 
the repression of proliferation associated genes (Zhang 
et al., 2008a). 
EBP1 also binds RNA and associates with 28S, 18S 
and 5.8S mature rRNAs, several rRNA precursors and 
probably U3 small nucleolar RNA. It has been 
implicated in the regulation of intermediate and late 
steps of rRNA processing (Squatrito et al., 2004; 
Squatrito et al., 2006). EBP1 also mediates cap-
independent translation of specific viral IRES (internal 
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regulates translation of AR mRNA (Zhou et al., 2010). 
EBP1 has also been implicated in protein stability via 
its interaction with the proteasome. Overexpression of 
EBP1 results in decreased stability of ErbB2 protein in 
breast cancer cells via a proteasome-mediated pathway 
(Lu et al., 2011). The long form of EBP1 binds to the 
p53 E3 ligase HDM2, enhancing HDM2-p53 
interactions and promoting p53 degradation (Kim et al., 
2011). 
The long (p48) and short (p42) forms of EBP1 have 
opposing biological effects, with the longer form 
inducing cell survival and the shorter form inhibiting 
cell growth (Liu et al., 2006). The long form binds 
HDM2, promoting degradation of p53 (Kim et al., 
2010). 
Homology 
Similar (30% identity) to the 42 kDA DNA binding 
protein SF00553 in S. pombe yeast (Yamada et al., 
1994) and StEBP1 in potato (Horvath et al., 2006). The 
orthologue in potatoes (StEBP1) has 69% sequence 
similarity to human EBP1 and can inhibit growth of 










Decreased expression of EBP1 is associated with 
higher tumor grade and metastasis in prostate cancer 
(Zhang et al., 2008b). However, another study 
indicated EBP1 expression increased with disease 
progression (Gannon et al., 2008). 
Breast cancer 
Prognosis 
Deletion of EBP1 results in tamoxifen resistance in 
breast cancer (Zhang et al., 2008a). However, patients 
with a high level of EBP1 protein have a poor clinical 
outcome (Ou et al., 2006). 
Glioblastoma 
Prognosis 
Glioblastoma patients expressing a high level of p48 
EBP1 have a worse prognosis than those expressing 
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